JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

JNJ

233.01

+1.03%↑

ISRG

478.71

-3.54%↓

ABT

108.96

-0.46%↓

RDY

13.8

+1.55%↑

NEOG

10.27

+0.39%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

147 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. veebr 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. veebr 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. veebr 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. veebr 2026, 23:23 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. veebr 2026, 22:57 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. veebr 2026, 21:51 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. veebr 2026, 21:49 UTC

Tulu

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. veebr 2026, 21:39 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:36 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. veebr 2026, 21:34 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. veebr 2026, 21:23 UTC

Tulu

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. veebr 2026, 21:19 UTC

Tulu

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. veebr 2026, 21:17 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. veebr 2026, 21:17 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:10 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. veebr 2026, 21:08 UTC

Tulu

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. veebr 2026, 21:07 UTC

Tulu

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Net $608.7M >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Rev $1.41B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q EPS 24c >PLTR

2. veebr 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.